Delivery architectures for oligonucleotide therapeutics in genetic and rare diseases: GalNAc-based hepatocyte targeting and extrahepatic translation
https://t.co/jYHVI7v9PQ
A multi-platform characterization of aggregation in morpholino oligonucleotide drug products: From soluble aggregates to subvisible particles
https://t.co/s53SyLBdab
Knockdown of the long isoform of the prolactin receptor selectively targets pathogenic immune cells in systemic lupus erythematosus and averts glomerular pathology
https://t.co/hYWXHsFGly
Inhibitors for a conserved filarial catechol-O-methyltransferase with potent efficacy against all life-stages of Brugia malayi infection in gerbils
https://t.co/OXmjycU6et
The small eyes of good effort zebrafish mutant result from a splicing defect in chromosome assembly factor 1, subunit b and persists upon Tp53 disruption
https://t.co/CHTahSoOug
Proteomic and transcriptomic analysis reveals an intracellular role for zona pellucida protein 2 in mouse morula-blastocyst transition
https://t.co/dqrcJpLxB8
Safety and efficacy of delpacibart zotadirsen in Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the USA (EXPLORE44): a randomised, placebo-controlled, double-blind, phase 1/2 trial
https://t.co/Xrv3FYKZef
Adverse effects of FDA-approved RNA therapeutics: a cross-platform analysis of RNA design, delivery systems, and safety profiles
https://t.co/uC5brAarCD